NCT01751360已完成3 期
SYR-472 Open-label Study
Takeda0 个研究点目标入组 14 人开始时间: 2013年4月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
- 主要终点
- Blood Glucose
研究概览
简要总结
To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.
- •The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.
排除标准
- •The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease
- •The participant is assessed to be ineligible for the study by the investigator or subinvestigator.
研究组 & 干预措施
SYR-472 100mg
Experimental
SYR-472 100mg
干预措施: SYR-472 (Drug)
结局指标
主要结局
Blood Glucose
时间窗: 7 days
Blood Glucose
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Double-blind Comparative Study of SYR-472Diabetes MellitusNCT01632007Takeda245
已完成
3 期
Long-term Study of SYR-472Diabetes MellitusNCT01431807Takeda680
已完成
2 期
Efficacy of SYR-472 in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00653185Takeda369
已完成
2 期
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes MellitusDiabetes MellitusNCT00760344Takeda386
已完成
3 期
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02324569Takeda240